Key Highlights

  • Total Revenue reached USD 21.72 million; the market had expected USD 18.70 million.
  • Loss per share of USD 0.16, where USD 0.21 was expected.
  • Net loss narrowed to USD 25.30 million from USD 40.97 million a year earlier.
  • Cash and cash equivalents totaled USD 189.2 million at September 30.

ADC Therapeutics (NYSE:ADCT) booked total revenue of USD 21.72 million in the third quarter of 2026. The market had expected USD 18.70 million, and the third quarter of 2025 produced USD 16.43 million. The company's loss per share was USD 0.16, against an expected USD 0.21 loss and a USD 0.30 loss a year before.

The net loss was USD 25.30 million, against USD 40.97 million in the prior-year quarter, and the loss from operations was USD 14.35 million, against USD 30.97 million.

How Product Sales Moved

Net product revenues rose from USD 15.8 million to USD 21.0 million, a gain of USD 5.3 million, or 33.4%. Cost of product sales went from USD 1.2 million to USD 2.0 million, a rise of USD 0.8 million, or 64.7%.

Total operating expenses came to USD 36.07 million, against USD 47.40 million. The filing's income statement puts nine-month total revenue, net, at USD 61.82 million, against USD 58.30 million.

Spending Lines Under the Microscope

Research and development spending fell to USD 14.7 million from USD 26.8 million, a decrease of USD 12.1 million, or 45.0%. Selling and Marketing expenses were USD 8.7 million, against USD 10.7 million, a decrease of USD 2.0 million, or 18.8%.

General and administrative costs moved the other way, to USD 10.7 million from USD 8.3 million, an increase of USD 2.4 million, or 28.9%. Over nine months the net loss was USD 74.84 million, against USD 136.21 million, and the loss from operations was USD 65.01 million, against USD 103.58 million.

Cash, Funding and Royalty Terms

At September 30, 2026, ADC Therapeutics held USD 189.2 million in cash and cash equivalents. It believes this position, together with its Capital resources, covers operations and capital needs for a minimum of twelve months from the report date.

The filing records that on February 18, 2026 the company amended the royalty purchase agreement it holds with funds run by HealthCare Royalty Management. Under that agreement it received USD 225.0 million in gross proceeds at closing, plus USD 75.0 million during 2023 once ZYNLONTA made its first commercial sale in the United Kingdom or in any country of the European Union. On August 15, 2022, it also agreed with its Loan lenders, under a Share Purchase Agreement, to buy 733,568 common shares.

The company adds that it is pushing into indolent lymphomas and earlier treatment lines, using trials it sponsors and studies started by investigators.